WO1998050556A3 - Intracellular production of hepatitis c e1 and e2 truncated polypeptides - Google Patents

Intracellular production of hepatitis c e1 and e2 truncated polypeptides Download PDF

Info

Publication number
WO1998050556A3
WO1998050556A3 PCT/US1998/009097 US9809097W WO9850556A3 WO 1998050556 A3 WO1998050556 A3 WO 1998050556A3 US 9809097 W US9809097 W US 9809097W WO 9850556 A3 WO9850556 A3 WO 9850556A3
Authority
WO
WIPO (PCT)
Prior art keywords
hepatitis
intracellular production
truncated polypeptides
truncated
polypeptides
Prior art date
Application number
PCT/US1998/009097
Other languages
French (fr)
Other versions
WO1998050556A2 (en
Inventor
Michael Hougton
Qui-Lim Choo
Sergio Abrignani
David Chien
Mark Selby
Edward Glazer
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to DE69841015T priority Critical patent/DE69841015D1/en
Priority to AU74716/98A priority patent/AU7471698A/en
Priority to AT98922096T priority patent/ATE437951T1/en
Priority to JP54836098A priority patent/JP4458556B2/en
Priority to EP98922096A priority patent/EP0980434B1/en
Priority to CA002288374A priority patent/CA2288374A1/en
Publication of WO1998050556A2 publication Critical patent/WO1998050556A2/en
Publication of WO1998050556A3 publication Critical patent/WO1998050556A3/en
Priority to HK00101959.7A priority patent/HK1023143A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/923—Cell culture

Abstract

Methods for obtaining recombinantly produced, C-terminally truncated, E1 and E2 polypeptides from cell lysates are disclosed. The intracellularly expressed truncated molecules display improved biological properties as compared to their secreted counterparts.
PCT/US1998/009097 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides WO1998050556A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE69841015T DE69841015D1 (en) 1997-05-06 1998-05-06 INTRA-CELLULAR PREPARATION OF SHORTENED HEPATITIS C POLYPEPTIDE E2
AU74716/98A AU7471698A (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides
AT98922096T ATE437951T1 (en) 1997-05-06 1998-05-06 INTRACELLULAR PRODUCTION OF SHORTENED HEPATITIS C-POLYPEPTIDE E2
JP54836098A JP4458556B2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis C E2 truncated polypeptide
EP98922096A EP0980434B1 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e2 truncated polypeptid
CA002288374A CA2288374A1 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides
HK00101959.7A HK1023143A1 (en) 1997-05-06 2000-03-30 Intracellular production of hepatitis c e2 truncated polypeptid

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4567597P 1997-05-06 1997-05-06
US60/045,675 1997-05-06

Publications (2)

Publication Number Publication Date
WO1998050556A2 WO1998050556A2 (en) 1998-11-12
WO1998050556A3 true WO1998050556A3 (en) 1999-02-11

Family

ID=21939272

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/009097 WO1998050556A2 (en) 1997-05-06 1998-05-06 Intracellular production of hepatitis c e1 and e2 truncated polypeptides

Country Status (10)

Country Link
US (2) US6521423B1 (en)
EP (1) EP0980434B1 (en)
JP (3) JP4458556B2 (en)
AT (1) ATE437951T1 (en)
AU (1) AU7471698A (en)
CA (1) CA2288374A1 (en)
DE (1) DE69841015D1 (en)
ES (1) ES2328536T3 (en)
HK (1) HK1023143A1 (en)
WO (1) WO1998050556A2 (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999066033A1 (en) * 1998-06-18 1999-12-23 The Government Of The United States Of America, Represented By The Secretary, Department Of Healtha Nd Human Services Surface targeted expression of a modified hepatitis c virus envelope protein
US6432411B1 (en) * 1999-07-13 2002-08-13 Hawaii Biotechnology Group Recombinant envelope vaccine against flavivirus infection
CA2389206C (en) 1999-10-27 2011-01-04 Chiron Corporation Activation of hcv-specific t cells
ES2319727T3 (en) * 1999-12-01 2009-05-12 Novartis Vaccines And Diagnostics, Inc. STIMULATION OF SPECIFIC ANTIBODIES OF HCV.
US7094882B2 (en) 2000-04-21 2006-08-22 Yeda Research And Development Co. Ltd. Growth factor which acts through erb b-4 rtk
CU23244A1 (en) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech VACCINATION FORMULATION POTENTIATED BY THE COMBINATION OF A DNA WITH AN ANTIGEN
AR045702A1 (en) 2001-10-03 2005-11-09 Chiron Corp COMPOSITIONS OF ASSISTANTS.
US8029803B2 (en) * 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2516403C (en) * 2003-01-17 2014-08-12 Aethlon Medical, Inc. Method for removal of viruses from blood by lectin affinity hemodialysis
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1574517A1 (en) * 2004-03-09 2005-09-14 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1602664A1 (en) * 2004-03-08 2005-12-07 Innogenetics N.V. HCV E1 comprising specific disulfide bridges
EP1783218A4 (en) * 2004-06-25 2009-02-18 Advanced Life Science Inst Inc Hcv rna having novel sequence
MX2007004662A (en) * 2004-10-18 2007-11-23 Globeimmune Inc Yeast-based therapeutic for chronic hepatitis c infection.
AU2006301846A1 (en) * 2005-10-13 2007-04-19 Akshaya Bio Inc. Chimeric antigen containing hepatitis C virus polypeptide and FC fragment for eliciting an immune response
WO2009076158A1 (en) 2007-12-07 2009-06-18 Novartis Ag Compositions for inducing immune responses
EP2331125A4 (en) 2008-09-19 2013-03-27 Globeimmune Inc Immunotherapy for chronic hepatitis c virus infection
CA2909586C (en) 2013-05-15 2021-08-31 The Governors Of The University Of Alberta E1e2 hcv vaccines and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008734A1 (en) * 1990-11-08 1992-05-29 Chiron Corporation Hepatitis c virus asialoglycoproteins
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074422C (en) 1987-11-18 2001-11-07 希龙股份有限公司 Nanbv diagnostics and vaccines
HU225068B1 (en) 1989-03-17 2006-05-29 Chiron Corp Process for producing diagnostics and vaccine of nanbh
MC2188A1 (en) 1989-05-18 1992-09-16 Chiron Corp NANBV DIAGNOSIS: POLYNUCLEOTIDES FOR SCREENING FOR HEPATITIS C VIRUS
US6274148B1 (en) * 1990-11-08 2001-08-14 Chiron Corporation Hepatitis C virus asialoglycoproteins
US6150134A (en) 1994-07-29 2000-11-21 Innogenetics, N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
CA2195312A1 (en) * 1994-07-29 1996-02-15 Mark Selby Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992008734A1 (en) * 1990-11-08 1992-05-29 Chiron Corporation Hepatitis c virus asialoglycoproteins
WO1996004301A2 (en) * 1994-07-29 1996-02-15 Chiron Corporation Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INUDOH M ET AL: "Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells", VACCINE, vol. 14, no. 17, December 1996 (1996-12-01), pages 1590-1596, XP004016818 *
MATSUURA, Y. ET AL.: "Expression of processed envelope protein of hepatitis C virus in mammalian and insect cells", JOURNAL OF VIROLOGY., vol. 66, no. 3, March 1992 (1992-03-01), ICAN SOCIETY FOR MICROBIOLOGY US, pages 1425 - 1431, XP002081580 *
SPAETE R R ET AL: "CHARACTERIZATION OF THE HEPATITIS C VIRUS E2/NS1 GENE PRODUCT EXPRESSED IN MAMMALIAN CELLS", VIROLOGY, vol. 188, June 1992 (1992-06-01), pages 819 - 830, XP000608114 *

Also Published As

Publication number Publication date
WO1998050556A2 (en) 1998-11-12
AU7471698A (en) 1998-11-27
DE69841015D1 (en) 2009-09-10
JP2009232863A (en) 2009-10-15
EP0980434B1 (en) 2009-07-29
JP2008195722A (en) 2008-08-28
JP4458556B2 (en) 2010-04-28
EP0980434A1 (en) 2000-02-23
ES2328536T3 (en) 2009-11-13
US7429385B2 (en) 2008-09-30
US6521423B1 (en) 2003-02-18
ATE437951T1 (en) 2009-08-15
US20040001854A1 (en) 2004-01-01
CA2288374A1 (en) 1998-11-12
HK1023143A1 (en) 2000-09-01
JP2002504810A (en) 2002-02-12

Similar Documents

Publication Publication Date Title
WO1998050556A3 (en) Intracellular production of hepatitis c e1 and e2 truncated polypeptides
WO1999002711A3 (en) Fusion proteins with an immunoglobulin hinge region linker
WO1995033819A3 (en) Cdk4 (cyclin dependent kinase 4) binding proteins
CA2155185A1 (en) Totally synthetic affinity reagents
WO2000053761A3 (en) Human cytokine as ligand of the zalpha receptor and uses thereof
WO1998021343A8 (en) Genes encoding telomerase proteins
WO2000018914A3 (en) Novel dkr polypeptides
TR200000175T2 (en) Preparation of erythropoietin with endogenic gene activation.
EP0913476A3 (en) Ornithine carbamoyl transferase sequence and uses thereof
CA2306449A1 (en) Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO2002059315A3 (en) Human nucleic acids and polypeptides and methods of use thereof
CA2336261A1 (en) Cyclin e2 genes and proteins
WO2001066690A3 (en) Novel compounds
WO2001072961A3 (en) Novel compounds
WO2001064837A3 (en) β NETRIN AND USES THEREOF
WO2000018909A3 (en) NUCLEIC ACIDS AND PROTEINS FROM $i(CENARCHAEUM SYMBIOSUM)
ZA978503B (en) Vertebrate smoothened proteins
AU2001238064A1 (en) 18477, a human protein kinase and uses therefor
AU5696796A (en) Recombinant preduodenal lipases and polypeptides derivatives produced by plants, processes for obtaining them and their uses
WO1999022005A3 (en) Heparan sulfate d-glucosaminyl 3-o-sulfotransferases, an uses therefor
EP1331265A3 (en) density enhanced protein tyrosine phosphatases
WO2002090500A3 (en) Novel human proteins, polynucleotides encoding them and methods of using the same
WO2002004600A3 (en) Novel compounds
WO2004089973A3 (en) Peptides, polypeptides, and proteins of reduced immunogenicity and methods for their production
WO2002046408A3 (en) Human proteins, polynucleotides encoding them and methods of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2288374

Country of ref document: CA

Ref country code: CA

Ref document number: 2288374

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 1998 548360

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998922096

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998922096

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642